THE PRIVATE LEDGERJoin our DiscordSubscribe
← All companies

Isomorphic Labs

Healthcare & Life Sciences · London, United Kingdom · Subsidiary

Isomorphic Labs applies AI to drug design and development, building on advances in protein-structure prediction.

Not disclosedLatest valuationSeries B terms were not disclosed
$2.1BLatest fundingMay 2026 Series B
PrivatePublic statusNo IPO announced
2021FoundedAlphabet spinout

The Company

Isomorphic Labs was founded to apply AI-native approaches to drug discovery and development. Its opportunity is to turn model capabilities into medicines, a task requiring both computational advances and clinical validation.

The May 2026 Series B is intended to move its platform and drug pipeline toward clinical-scale work. The company did not disclose a valuation, so this profile does not substitute an estimate for a confirmed figure.

Why It Matters

Isomorphic Labs sits at the intersection of private AI investment and biotechnology. Its progress could reshape drug-development timelines and affects the strategic position of pharmaceutical partners, Alphabet, and the broader AI-biology ecosystem.

Valuation History

  1. Raised $600M · valuation undisclosed→Mar 2025First external roundSource ↗
  2. Raised $2.1B · valuation undisclosed→May 2026Series BSource ↗

What Changed

  1. Isomorphic Labs launches as a Google DeepMind spinout.

  2. Pharmaceutical partnerships validate demand for AI-led drug discovery.

  3. The company raises its first external financing.

  4. A $2.1 billion Series B funds the move toward applying models at scale.

Last verified by human:

THE NEXT COMPANY. A CLEARER PICTURE.

Get the next breakdown.

Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.

Copy this link

Your browser could not copy automatically. Select and copy the link below.